Q1 EPS Forecast for Vanda Pharmaceuticals Lowered by Analyst

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities research analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Vanda Pharmaceuticals in a research report issued on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of ($0.52) for the quarter, down from their prior forecast of ($0.13). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.93) EPS and FY2026 earnings at $0.22 EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06. The business had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%.

Separately, StockNews.com began coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA opened at $4.55 on Thursday. The firm’s 50-day moving average is $4.60 and its 200-day moving average is $4.83. The company has a market cap of $265.36 million, a price-to-earnings ratio of -14.22 and a beta of 0.74. Vanda Pharmaceuticals has a 52-week low of $3.71 and a 52-week high of $6.75.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its position in shares of Vanda Pharmaceuticals by 10.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock valued at $11,920,000 after acquiring an additional 227,428 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Vanda Pharmaceuticals by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 1,450,310 shares of the biopharmaceutical company’s stock valued at $6,949,000 after purchasing an additional 24,483 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Vanda Pharmaceuticals by 4.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company’s stock valued at $3,925,000 after purchasing an additional 38,449 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Vanda Pharmaceuticals by 1.4% in the 4th quarter. Federated Hermes Inc. now owns 726,619 shares of the biopharmaceutical company’s stock valued at $3,481,000 after purchasing an additional 9,840 shares during the period. Finally, Millennium Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 67.4% in the 4th quarter. Millennium Management LLC now owns 668,693 shares of the biopharmaceutical company’s stock worth $3,203,000 after buying an additional 269,183 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.